Rapport Therapeutics, Inc. - Common Stock (RAPP) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
RAPP on Nasdaq
Shares outstanding
47,664,990
Price per share
$27.10
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
28,333,513
Total reported value
$859,635,746
% of total 13F portfolios
0%
Share change
+1,962,822
Value change
+$59,830,423
Number of holders
92
Price from insider filings
$27.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Rapport Therapeutics, Inc. - Common Stock (RAPP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Third Rock Ventures V, L.P. 20% $81,198,952 7,135,233 Third Rock Ventures V, L.P. 31 Dec 2024
Cormorant Asset Management, LP 6.7% $94,817,874 3,192,521 Cormorant Asset Management, LP 30 Sep 2025
BlackRock, Inc. 5% $72,741,637 2,397,549 BlackRock, Inc. 31 Dec 2025
Sofinnova Venture Partners XI, L.P. 4.2% $29,155,258 1,947,579 Dr. James I. Healy ("Healy") 11 Sep 2025
JOHNSON & JOHNSON 4.9% $53,000,690 1,784,517 JOHNSON & JOHNSON 30 Sep 2025

As of 31 Dec 2025, 92 institutional investors reported holding 28,333,513 shares of Rapport Therapeutics, Inc. - Common Stock (RAPP). This represents 59% of the company’s total 47,664,990 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Rapport Therapeutics, Inc. - Common Stock (RAPP) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TRV GP V, LLC 15% 7,135,233 0% 50% $216,482,969
Capital International Investors 7.1% 3,402,529 0% 0.02% $103,232,730
GOLDMAN SACHS GROUP INC 6.3% 3,001,879 +24% 0.01% $91,077,009
BlackRock, Inc. 5.1% 2,431,862 +55% 0% $73,782,693
Sofinnova Investments, Inc. 4% 1,904,408 -2.2% 2.5% $57,779,739
VANGUARD GROUP INC 3.8% 1,817,757 +12% 0% $55,150,747
JOHNSON & JOHNSON 3.7% 1,784,517 0% 9.8% $54,142,246
TRV GP VI, LLC 2% 969,218 0% 20% $29,406,074
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 2% 952,371 +6.7% 0.01% $28,894,936
STATE STREET CORP 1.5% 714,821 +92% 0% $21,687,669
Siren, L.L.C. 1.5% 708,469 -33% 0.64% $21,494,949
GEODE CAPITAL MANAGEMENT, LLC 1.5% 694,734 +30% 0% $21,081,433
PRUDENTIAL FINANCIAL INC 0.53% 254,967 0.01% $7,735,699
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.51% 244,391 +21% 0% $7,414,823
UBS Group AG 0.47% 226,360 -59% 0% $6,867,763
MORGAN STANLEY 0.44% 210,331 -23% 0% $6,381,444
Ensign Peak Advisors, Inc 0.41% 194,200 0% 0.01% $5,892,028
KENNEDY CAPITAL MANAGEMENT LLC 0.37% 178,737 0.11% $5,422,881
RENAISSANCE TECHNOLOGIES LLC 0.25% 118,814 +237% 0.01% $3,604,817
TD Asset Management Inc 0.24% 115,190 -16% 0% $3,494,865
Swedbank AB 0.24% 113,200 0% $3,434,488
Informed Momentum Co LLC 0.18% 85,555 -2% 0.29% $2,595,739
DIMENSIONAL FUND ADVISORS LP 0.18% 83,487 +637% 0% $2,532,996
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.17% 78,659 -4.5% 0% $2,407,086
Bank of New York Mellon Corp 0.16% 74,081 +56% 0% $2,247,618

Institutional Holders of Rapport Therapeutics, Inc. - Common Stock (RAPP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 28,333,513 $859,635,746 +$59,830,423 $30.34 92
2025 Q3 49,276,697 $1,463,478,389 +$335,895,383 $29.70 123
2025 Q2 38,494,803 $437,875,302 +$4,896,059 $11.37 81
2025 Q1 38,102,588 $382,320,591 +$11,241,443 $10.03 77
2024 Q4 36,577,539 $648,890,836 -$29,671 $17.74 69
2024 Q3 28,444,042 $581,877,476 +$37,552,009 $20.48 55
2024 Q2 25,558,517 $593,435,106 +$593,435,106 $23.26 35